BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rahman MA, Kyriazanos ID, Ono T, Yamanoi A, Kohno H, Tsuchiya M, Nagasue N. Impact of PTEN expression on the outcome of hepatitis C virus-positive cirrhotic hepatocellular carcinoma patients: possible relationship with COX II and inducible nitric oxide synthase. Int J Cancer. 2002;100:152-157. [PMID: 12115563 DOI: 10.1002/ijc.10458] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 2.1] [Reference Citation Analysis]
Number Citing Articles
1 Su LJ, Ding GW, Yang ZL, Zhang SB, Yang YX, Xu CS. Expression patterns and action analysis of genes associated with hepatitis virus infection during rat liver regeneration. World J Gastroenterol 2006; 12(47): 7626-7634 [PMID: 17171791 DOI: 10.3748/wjg.v12.i47.7626] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
2 Kim SG, Seo SH, Shin JH, Yang JP, Lee SH, Shin EH. Increase in the nuclear localization of PTEN by the Toxoplasma GRA16 protein and subsequent induction of p53-dependent apoptosis and anticancer effect. J Cell Mol Med 2019;23:3234-45. [PMID: 30834688 DOI: 10.1111/jcmm.14207] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
3 Nakae D, Uematsu F, Kishida H, Kusuoka O, Katsuda S, Yoshida M, Takahashi M, Maekawa A, Denda A, Konishi Y, Kotake Y, Floyd RA. Inhibition of the development of hepatocellular carcinomas by phenyl N-tert-butyl nitrone in rats fed with a choline-deficient, l-amino acid-defined diet. Cancer Letters 2004;206:1-13. [DOI: 10.1016/j.canlet.2003.10.003] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
4 Cotler SJ, Hay N, Xie H, Chen ML, Xu PZ, Layden TJ, Guzman G. Immunohistochemical Expression of Components of the Akt-mTORC1 Pathway is Associated with Hepatocellular Carcinoma in Patients with Chronic Liver Disease. Dig Dis Sci 2008;53:844-9. [DOI: 10.1007/s10620-007-9934-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
5 Mohanty S, Jensen D. Tumor Markers and Molecular Biology. In: Al Knawy B, Reddy K, Bolondi L, editors. Hepatocellular Carcinoma. CRC Press; 2009. pp. 62-81. [DOI: 10.3109/9780203092880-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
6 Grech G, Zhan X, Yoo BC, Bubnov R, Hagan S, Danesi R, Vittadini G, Desiderio DM. EPMA position paper in cancer: current overview and future perspectives. EPMA J 2015;6:9. [PMID: 25908947 DOI: 10.1186/s13167-015-0030-6] [Cited by in Crossref: 56] [Cited by in F6Publishing: 55] [Article Influence: 8.0] [Reference Citation Analysis]
7 Clément S, Peyrou M, Sanchez-Pareja A, Bourgoin L, Ramadori P, Suter D, Vinciguerra M, Guilloux K, Pascarella S, Rubbia-Brandt L, Negro F, Foti M. Down-regulation of phosphatase and tensin homolog by hepatitis C virus core 3a in hepatocytes triggers the formation of large lipid droplets. Hepatology 2011;54:38-49. [PMID: 21465511 DOI: 10.1002/hep.24340] [Cited by in Crossref: 53] [Cited by in F6Publishing: 52] [Article Influence: 4.8] [Reference Citation Analysis]
8 Peyrou M, Bourgoin L, Foti M. PTEN in liver diseases and cancer. World J Gastroenterol 2010; 16(37): 4627-4633 [PMID: 20872961 DOI: 10.3748/wjg.v16.i37.4627] [Cited by in CrossRef: 56] [Cited by in F6Publishing: 47] [Article Influence: 4.7] [Reference Citation Analysis]
9 McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Montalto G, Cervello M, Nicoletti F, Fagone P, Malaponte G, Mazzarino MC, Candido S, Libra M, Bäsecke J, Mijatovic S, Maksimovic-Ivanic D, Milella M, Tafuri A, Cocco L, Evangelisti C, Chiarini F, Martelli AM. Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. Oncotarget 2012;3:954-87. [PMID: 23006971 DOI: 10.18632/oncotarget.652] [Cited by in Crossref: 190] [Cited by in F6Publishing: 176] [Article Influence: 21.1] [Reference Citation Analysis]
10 Lee M, Ko H, Yun M. Cancer Metabolism as a Mechanism of Treatment Resistance and Potential Therapeutic Target in Hepatocellular Carcinoma. Yonsei Med J 2018;59:1143-9. [PMID: 30450847 DOI: 10.3349/ymj.2018.59.10.1143] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
11 Horiike S, Kawanishi S, Kaito M, Ma N, Tanaka H, Fujita N, Iwasa M, Kobayashi Y, Hiraku Y, Oikawa S. Accumulation of 8-nitroguanine in the liver of patients with chronic hepatitis C. J Hepatol. 2005;43:403-410. [PMID: 16023246 DOI: 10.1016/j.jhep.2005.03.026] [Cited by in Crossref: 54] [Cited by in F6Publishing: 43] [Article Influence: 3.2] [Reference Citation Analysis]
12 Hao LS, Zhang XL. Advances in PTEN and hepatic diseases. Shijie Huaren Xiaohua Zazhi 2008; 16(17): 1904-1911 [DOI: 10.11569/wcjd.v16.i17.1904] [Reference Citation Analysis]
13 Kang-Park S, Im JH, Lee JH, Lee YI. PTEN modulates hepatitis B virus-X protein induced survival signaling in Chang liver cells. Virus Res. 2006;122:53-60. [PMID: 16872708 DOI: 10.1016/j.virusres.2006.06.010] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.3] [Reference Citation Analysis]
14 Mann CD, Neal CP, Garcea G, Manson MM, Dennison AR, Berry DP. Prognostic molecular markers in hepatocellular carcinoma: a systematic review. Eur J Cancer. 2007;43:979-992. [PMID: 17291746 DOI: 10.1016/j.ejca.2007.01.004] [Cited by in Crossref: 171] [Cited by in F6Publishing: 156] [Article Influence: 11.4] [Reference Citation Analysis]
15 Zhuravleva E, Tschopp O, Hemmings BA. Role of PKB/Akt in Liver Diseases. In: Dufour J, Clavien P, editors. Signaling Pathways in Liver Diseases. Berlin: Springer Berlin Heidelberg; 2010. pp. 243-59. [DOI: 10.1007/978-3-642-00150-5_16] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
16 Khalid A, Hussain T, Manzoor S, Saalim M, Khaliq S. PTEN: A potential prognostic marker in virus-induced hepatocellular carcinoma. Tumour Biol 2017;39:101042831770575. [DOI: 10.1177/1010428317705754] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
17 Hollander MC, Blumenthal GM, Dennis PA. PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat Rev Cancer. 2011;11:289-301. [PMID: 21430697 DOI: 10.1038/nrc3037] [Cited by in Crossref: 526] [Cited by in F6Publishing: 512] [Article Influence: 47.8] [Reference Citation Analysis]
18 Du Y, Zhang YW, Pu R, Han X, Hu JP, Zhang HW, Wang HY, Cao GW. Phosphatase and tensin homologue genetic polymorphisms and their interactions with viral mutations on the risk of hepatocellular carcinoma. Chin Med J (Engl) 2015;128:1005-13. [PMID: 25881591 DOI: 10.4103/0366-6999.155057] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
19 Liu HY, Pedros C, Kong KF, Canonigo-Balancio AJ, Xue W, Altman A. Leveraging the Treg-intrinsic CTLA4-PKCη signaling pathway for cancer immunotherapy. J Immunother Cancer 2021;9:e002792. [PMID: 34588224 DOI: 10.1136/jitc-2021-002792] [Reference Citation Analysis]
20 Rountree CB, Ding W, He L, Stiles B. Expansion of CD133-expressing liver cancer stem cells in liver-specific phosphatase and tensin homolog deleted on chromosome 10-deleted mice. Stem Cells. 2009;27:290-299. [PMID: 19008348 DOI: 10.1634/stemcells.2008-0332] [Cited by in Crossref: 70] [Cited by in F6Publishing: 70] [Article Influence: 5.4] [Reference Citation Analysis]
21 Leslie J, Geh D, Elsharkawy AM, Mann DA, Vacca M. Metabolic dysfunction and cancer in HCV: shared pathways and mutual interactions. Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2022.01.029] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Clément S, Peyrou M, Foti M, Negro F. Statins May Protect Against Hepatocellular Carcinoma Development in Patients Infected With Hepatitis C Virus, but What Are the Mechanisms? JCO 2013;31:4160-1. [DOI: 10.1200/jco.2013.51.0354] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
23 Imai T, Hasumura M, Cho YM, Onose J, Hirose M. Depression of T cell-mediated immunity reduces sulfadimethoxine-induced capsular inflammation and inhibits associated development of invasive thyroid follicular cell carcinomas in rats. Cancer Sci 2007;98:294-8. [PMID: 17270018 DOI: 10.1111/j.1349-7006.2007.00406.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
24 Zhou J, Li X. Association of PTEN expression with liver function and inflammatory changes in patients with liver cancer after chemotherapy. Oncol Lett 2018;16:6633-7. [PMID: 30405802 DOI: 10.3892/ol.2018.9458] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Luongo F, Colonna F, Calapà F, Vitale S, Fiori ME, De Maria R. PTEN Tumor-Suppressor: The Dam of Stemness in Cancer. Cancers (Basel) 2019;11:E1076. [PMID: 31366089 DOI: 10.3390/cancers11081076] [Cited by in Crossref: 44] [Cited by in F6Publishing: 46] [Article Influence: 14.7] [Reference Citation Analysis]
26 Watanabe S, Horie Y, Kataoka E, Sato W, Dohmen T, Ohshima S, Goto T, Suzuki A. Non-alcoholic steatohepatitis and hepatocellular carcinoma: lessons from hepatocyte-specific phosphatase and tensin homolog (PTEN)-deficient mice. J Gastroenterol Hepatol. 2007;22 Suppl 1:S96-S100. [PMID: 17567478 DOI: 10.1111/j.1440-1746.2006.04665.x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 49] [Article Influence: 3.5] [Reference Citation Analysis]
27 Khan S, Zhang D, Zhang J, Hayat MK, Ren J, Nasir S, Fawad M, Bai Q. The Key Role of microRNAs in Initiation and Progression of Hepatocellular Carcinoma. Front Oncol 2022;12:950374. [DOI: 10.3389/fonc.2022.950374] [Reference Citation Analysis]
28 Steelman LS, Stadelman KM, Chappell WH, Horn S, Bäsecke J, Cervello M, Nicoletti F, Libra M, Stivala F, Martelli AM, McCubrey JA. Akt as a therapeutic target in cancer. Expert Opin Ther Targets 2008;12:1139-65. [PMID: 18694380 DOI: 10.1517/14728222.12.9.1139] [Cited by in Crossref: 101] [Cited by in F6Publishing: 99] [Article Influence: 7.2] [Reference Citation Analysis]
29 Eritja N, Santacana M, Maiques O, Gonzalez-Tallada X, Dolcet X, Matias-Guiu X. Modeling glands with PTEN deficient cells and microscopic methods for assessing PTEN loss: endometrial cancer as a model. Methods 2015;77-78:31-40. [PMID: 25461816 DOI: 10.1016/j.ymeth.2014.11.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
30 Xu CS, Zhang SB, Chen XG, Rahman S. Correlation analysis of liver tumor-associated genes with liver regeneration. World J Gastroenterol 2007; 13(24): 3323-3332 [PMID: 17659671 DOI: 10.3748/wjg.v13.i24.3323] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
31 Vinciguerra M, Foti M. PTEN at the crossroad of metabolic diseases and cancer in the liver. Annals of Hepatology 2008;7:192-9. [DOI: 10.1016/s1665-2681(19)31848-4] [Cited by in Crossref: 38] [Article Influence: 2.7] [Reference Citation Analysis]
32 Cervello M, McCubrey JA, Cusimano A, Lampiasi N, Azzolina A, Montalto G. Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. Oncotarget 2012;3:236-60. [PMID: 22470194 DOI: 10.18632/oncotarget.466] [Cited by in Crossref: 123] [Cited by in F6Publishing: 122] [Article Influence: 12.3] [Reference Citation Analysis]
33 Lah JJ, Cui W, Hu KQ. Effects and mechanisms of silibinin on human hepatoma cell lines. World J Gastroenterol 2007; 13(40): 5299-5305 [PMID: 17879397 DOI: 10.3748/wjg.v13.i40.5299] [Cited by in CrossRef: 65] [Cited by in F6Publishing: 60] [Article Influence: 4.3] [Reference Citation Analysis]
34 Cheng D, Zhang L, Yang G, Zhao L, Peng F, Tian Y, Xiao X, Chung RT, Gong G. Hepatitis C virus NS5A drives a PTEN-PI3K/Akt feedback loop to support cell survival. Liver Int. 2015;35:1682-1691. [PMID: 25388655 DOI: 10.1111/liv.12733] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
35 Steelman LS, Chappell WH, Abrams SL, Kempf RC, Long J, Laidler P, Mijatovic S, Maksimovic-Ivanic D, Stivala F, Mazzarino MC, Donia M, Fagone P, Malaponte G, Nicoletti F, Libra M, Milella M, Tafuri A, Bonati A, Bäsecke J, Cocco L, Evangelisti C, Martelli AM, Montalto G, Cervello M, McCubrey JA. Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging (Albany NY) 2011;3:192-222. [PMID: 21422497 DOI: 10.18632/aging.100296] [Cited by in Crossref: 366] [Cited by in F6Publishing: 367] [Article Influence: 33.3] [Reference Citation Analysis]
36 Sanchez-Pareja A, Clément S, Peyrou M, Spahr L, Negro F, Rubbia-Brandt L, Foti M. Phosphatase and tensin homolog is a differential diagnostic marker between nonalcoholic and alcoholic fatty liver disease. World J Gastroenterol 2016; 22(14): 3735-3745 [PMID: 27076758 DOI: 10.3748/wjg.v22.i14.3735] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
37 Simioni C, Martelli AM, Cani A, Cetin-Atalay R, McCubrey JA, Capitani S, Neri LM. The AKT inhibitor MK-2206 is cytotoxic in hepatocarcinoma cells displaying hyperphosphorylated AKT-1 and synergizes with conventional chemotherapy. Oncotarget 2013;4:1496-506. [PMID: 24036604 DOI: 10.18632/oncotarget.1236] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 5.1] [Reference Citation Analysis]
38 Tu K, Liu Z, Yao B, Han S, Yang W. MicroRNA-519a promotes tumor growth by targeting PTEN/PI3K/AKT signaling in hepatocellular carcinoma. Int J Oncol 2016;48:965-74. [PMID: 26708293 DOI: 10.3892/ijo.2015.3309] [Cited by in Crossref: 69] [Cited by in F6Publishing: 70] [Article Influence: 9.9] [Reference Citation Analysis]
39 Chen J, Du YJ. Advances in understanding the role of cyclooxygenase-2 in the pathogenesis of liver diseases. Shijie Huaren Xiaohua Zazhi 2011; 19(13): 1321-1325 [DOI: 10.11569/wcjd.v19.i13.1321] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
40 N/A. N/A. Shijie Huaren Xiaohua Zazhi 2004; 12(2): 417-419 [DOI: 10.11569/wcjd.v12.i2.417] [Reference Citation Analysis]
41 Kurokawa Y, Matoba R, Takemasa I, Nakamori S, Tsujie M, Nagano H, Dono K, Umeshita K, Sakon M, Ueno N. Molecular features of non-B, non-C hepatocellular carcinoma: a PCR-array gene expression profiling study. J Hepatol. 2003;39:1004-1012. [PMID: 14642619 DOI: 10.1016/s0168-8278(03)00473-2] [Cited by in Crossref: 34] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
42 Goossens N, Negro F. Is genotype 3 of the hepatitis C virus the new villain? Hepatology 2014;59:2403-12. [PMID: 24155107 DOI: 10.1002/hep.26905] [Cited by in Crossref: 97] [Cited by in F6Publishing: 90] [Article Influence: 12.1] [Reference Citation Analysis]